Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies

Frontiers in Pharmacology
Jia YangJun Zhou

Abstract

B lymphocytes play a critical role in humoral immunity. Abnormal B cell development and function cause a variety of hematological malignancies such as myeloma, B cell lymphoma, and leukemia. Histone deacetylase 6 (HDAC6) inhibitors alone or in combination with other drugs have shown efficacy in several hematological malignancies, including those resistant to targeted therapies. Mechanistically, HDAC6 inhibitors promote malignant tumor cell apoptosis by inhibiting protein degradation, reinvigorating anti-tumor immunity, and inhibiting cell survival signaling pathways. Due to their specificity, HDAC6 inhibitors represent a very promising and feasible new development pipeline for high-efficacy drugs with limited side effects. This article reviews recent progress in the mechanisms of action of HDAC6 inhibitors for the treatment of B cell-associated hematological malignancies, such as multiple myeloma and B cell non-Hodgkin lymphoma, which are often resistant to targeted therapies.

References

May 25, 2002·Nature·Charlotte HubbertTso-Pang Yao
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Feb 28, 2003·The EMBO Journal·Yu ZhangPatrick Matthias
Apr 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Stephen J HaggartyStuart L Schreiber
Jan 22, 2005·Immunological Reviews·Mary Ellen ConleySheila A Shurtleff
Jun 7, 2005·Proceedings of the National Academy of Sciences of the United States of America·Teru HideshimaKenneth C Anderson
Jul 24, 2007·Molecular Cell·Xiaohong ZhangEdward Seto
Sep 18, 2007·Advances in Immunology·John G Monroe, Kenneth Dorshkind
Jan 9, 2008·Molecular and Cellular Biology·Yu ZhangPatrick Matthias
Mar 22, 2008·The Journal of Biological Chemistry·Yu LiMichael J Comb
Jun 1, 2007·Molecular Oncology·Santiago Ropero, Manel Esteller
May 15, 2009·Histopathology·Lena MarquardElisabeth Ralfkiaer
Jan 25, 2011·Bioorganic & Medicinal Chemistry Letters·Eunhyun ChoiGyoonhee Han
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik NogaiGeorg Lenz
Jun 28, 2011·Leukemia & Lymphoma·Grace I Aldana-MasangkayKathleen M Sakamoto
Jan 13, 2012·Oncology·J C WangS Lichter
Feb 16, 2012·The Journal of Biological Chemistry·Matthew T RioloRachel A Altura
Nov 13, 2013·The Journal of Clinical Investigation·Tint LwinJianguo Tao
Aug 1, 2014·International Journal of Medical Sciences·Sung Hak LeeJinyoung Yoo
Dec 9, 2014·Epigenetics : Official Journal of the DNA Methylation Society·Sridurga MithraprabhuAndrew Spencer
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Güllü GörgünKenneth C Anderson
Jun 28, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer E AmengualOwen A O'Connor
Jul 15, 2015·Journal of Hematology & Oncology·Min-Wu ChaoChe-Ming Teng
Jan 19, 2016·Molecular Oncology·Lienlaf MVillagra A
Jan 23, 2016·Current Opinion in Immunology·Lynn M Corcoran, David M Tarlinton
Apr 21, 2016·The Cochrane Database of Systematic Reviews·Kathleen ScottImelda Coyne
Apr 28, 2016·Pharmacology & Therapeutics·Linlin ZhangJun Zhou
Nov 2, 2016·Proceedings of the National Academy of Sciences of the United States of America·Teru HideshimaJames E Bradner
Jan 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dan T VoglSagar Lonial

❮ Previous
Next ❯

Citations

Jan 4, 2021·Journal of Clinical Laboratory Analysis·Huixian MaWei Xie

❮ Previous
Next ❯

Methods Mentioned

BETA
histone acetylation
nuclear translocation
xenograft
acetylation

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis